Editas Medicine

ISIN US28106W1036

 | 

WKN A2AC4K

Market cap (in EUR)
103.18 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
 

Overview

Description

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.
Show more Show less
Healthcare Biopharmaceuticals Non-System-Specific Biopharmaceuticals United States

Financials

Key metrics

Market capitalisation, EUR 103.18 m
EPS, EUR -2.67
P/B ratio 0.86
P/E ratio -
Dividend yield 0.00%

Income statement (2024)

Revenue, EUR 29.87 m
Net income, EUR -219.19 m
Profit margin -733.72%

What ETF is Editas Medicine in?

There are 7 ETFs which contain Editas Medicine. All of these ETFs are listed in the table below. The ETF with the largest weighting of Editas Medicine is the WisdomTree BioRevolution UCITS ETF USD Acc.
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.